Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The autophagosome–lysosome fusion process is a critical step in macroautophagy, a conserved catabolic pathway in eukaryotic cells. During this process, cytoplasmic material is first sequestered into double-membrane vesicles called autophagosomes. These autophagosomes then fuse with lysosomes to form autolysosomes, where the cargo is degraded by lysosomal enzymes. This fusion event ensures the breakdown and recycling of cellular components, maintaining cellular homeostasis. Key molecular players include SNARE proteins (Stx17, SNAP29, VAMP8), Rab7, HOPS complex, ATG14, and INPP5E. Defects in this process are linked to various diseases, including neurodegenerative disorders and cancer.
Inhibition of autophagosome-lysosome fusion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autophagosome-Lysosome Fusion Process.